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Background and aims: While inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) is known
to result in dramatic lowering of LDL-cholesterol (LDL-C), it is poorly understood how it affects other lipid
species and their metabolism. The aim of this study was to characterize the alterations in the lipidome of
plasma and lipoprotein particles after administration of PCSK9 inhibiting antibody to patients with
established coronary heart disease.
Methods: Plasma samples were obtained from patients undergoing a randomized placebo-controlled
phase II trial (EQUATOR) for the safe and effective use of RG7652, a fully human monoclonal antibody
inhibiting PCSK9 function. Lipoprotein fractions were isolated by sequential density ultracentrifugation,
and both plasma and major lipoprotein classes (VLDL-IDL, LDL, HDL) were subjected to mass spectro-
metric lipidomic profiling.
Results: PCSK9 inhibition significantly decreased plasma levels of several lipid classes, including
sphingolipids (dihydroceramides, glucosylceramides, sphingomyelins, ceramides), cholesteryl esters and
free cholesterol. Previously established ceramide ratios predicting cardiovascular mortality, or inflam-
mation related eicosanoid lipids, were not altered. RG7652 treatment also affected the overall and
relative distribution of lipids in lipoprotein classes. An overall decrease of total lipid species was observed
in LDL and VLDL þ IDL particles, while HDL-associated phospholipids increased. Following the treatment,
LDL displayed reduced lipid cargo, whereas relative lipid proportions of the VLDL þ IDL particles were
mostly unchanged, and there were relatively more lipids carried in the HDL particles.
Conclusions: Administration of PCSK9 antibody significantly alters the lipid composition of plasma and
lipoprotein particles. These changes further shed light on the link between anti-PCSK9 therapies and
cardiovascular risk.
© 2018 Elsevier B.V. All rights reserved.cholesteryl ester; Cer, ceramide; DAG, diacylglycerol; Gb3, globotriasoylceramide; Glc/GalCer, glucosyl/galactosylcer-
de; LDL-C, LDL-cholesterol; LPC, lysophosphatidylcholine; LOF, loss-of-function; HDL-C, HDL-cholesterol; PC, phos-
hosphatidylinositol; SM, sphingomyelin; TAG, triacylglycerol; TC, total cholesterol; TG, triglyceride.
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Table 1
Baseline characteristics of the study cohort (N¼ 40).
RG7652 Placebo p-value
No of subjects 25 15 e
Age 64.0 (56.0e70.0) 67.0 (61.5e69.5) 0.393
BMI 29.1 (24.8e31.2) 29.1 (26.9e31.1) 0.489
Gender
Male 15 (60%) 8 (53%) e
Female 10 (40%) 7 (47%) e
Statin
Yes 15 (60%) 11 (73%) e
No 10 (40%) 4 (27%) e
Treatment
400mg/4W 5 (20%) 0 (0%) e
400mg/8W 6 (24%) 0 (0%) e
800mg/8W 11 (44%) 0 (0%) e
800mg/12W 3 (12%) 0 (0%) e
Placebo 0 (0%) 15 (100%) e
TC (mg/dL) 211 (188e241) 208 (178e215) 0.295
LDL-C (mg/dL) 126 (108e159) 132 (112e153) 0.989
HDL-C (mg/dL) 45 (36e57) 54 (46e61) 0.281
TG (mg/dL) 159 (113e182) 113 (85e132) 0.046
ApoA1 (mg/dL) 136 (122e162) 145 (130e169) 0.364
Values for continuous variables represent median and interquartile range.
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Atherosclerosis and coronary artery disease (CAD) are associ-
ated with increased plasma low-density lipoprotein cholesterol
(LDL-C) concentration and inflammatory processes within the
atherosclerotic lipid-laden lesions [1]. Statins arewidely used drugs
to reduce cholesterol levels and they also possess anti-
inflammatory properties. However, in some patients statin treat-
ment does not result in sufficient LDL-C reduction and the use of
statins is quite commonly restricted due to side effects, such as
muscle pain, fatigue and weakness [2]. Moreover, statins are
associated with development of diabetes [3], and therefore new
drugs are being developed that would further inhibit the athero-
sclerotic processes with fewer side effects.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) has
gained interest as a new therapeutic target for coronary heart
disease after it was discovered that gain-of-function (GOF) muta-
tions in the PCSK9 gene lead to hypercholesterolemia [4] whereas
loss-of-function (LOF) mutations are associated with hypo-
cholesterolemia and reduced risk of developing coronary heart
disease [5]. PCSK9 is highly expressed in liver and regulates LDL-C
levels by enhancing lysosomal degradation of the hepatic low-
density lipoprotein receptors (LDLRs) [6]. Therapeutic approaches
are based on the inhibition of PCSK9 function, and the major stra-
tegies for inhibition include anti-PCSK9 antibodies, small molecule
inhibitors and antisense oligonucleotide gene silencing approaches
[7]. Recently, the first outcome trial with an anti-PCSK9 antibody
showed reduction in non-fatal cardiovascular events [8].
While the effect of PCSK9 function on LDL-C and cholesterol
metabolism has been intensively investigated, its role in meta-
bolism of other lipid species has been underexplored, despite the
evidence suggesting that inhibition of PCSK9 may cause profound
changes in lipid metabolism. For instance, previous findings from
our laboratory from a transgenic mouse model showed that several
sphingolipid species were affected by PCSK9 deficiency [9]. Notably,
in human serum several lipid species were decreased non-
proportionally to LDL-C reduction [9,10]. This raises the possibil-
ity that PCSK9 deficiency may reduce atherosclerosis via reduction
of LDL-C concentration as well as by changes in levels of other lipid
classes.
To further investigate the role of PCSK9 in regulating lipid
metabolism, we performed lipidomic analysis in human subjects
enrolled in Phase II trial for RG7652, a fully human IgG1monoclonal
antibody that prevents the binding of PCSK9 to hepatic LDLR,
thereby increasing the cell surface expression of the LDLR and
enhancing LDL-C clearance. To better understand the observed
changes in response to treatment with RG7652, whole plasma as
well as major plasma lipoprotein classes, VLDL þ IDL, LDL or HDL,
were profiled in this study.
2. Materials and methods
2.1. Patients and samples
Fasting plasma samples at baseline and 29 days after treatment
were obtained from 40 non-diabetic patients (Table 1) with
established coronary heart disease (CHD)whowere participating in
a randomized, double-blind, phase II trial (EQUATOR) investigating
safe and effective use of RG7652, a monoclonal antibody against
PCSK9 [11]. Early time point of day 29was chosen, as the aimwas to
investigate acute changes of the lipidome, after single administra-
tion of RG7652 that still reflected robust and stable LDL-lowering
effect [11]. The EQUATOR trial (clinicaltrials.gov: NCT01609140)
was performed in accordance with the International Conference
and Harmonization guidelines and the Declaration of Helsinki, andall patients provided written informed consent by local institu-
tional review boards/ethics committees. The patients in this sub-
population of the EQUATOR trial were receiving four different dose-
regimens of RG7652 administration (Table 1) that were equally
effective in lowering LDL-C [11], and for the statistical analyses all
samples from treated groups were pooled into a single set of pa-
tients. Altogether 25 patients were receiving RG7652 and 15 pla-
cebo (Table 1). The criteria for patient selection was as follows: no
diabetes, chronic kidney disease, or familiar hypercholesterolemia
and all were Caucasians. RG7652 and placebo groups for the study
were well matched for cholesterol levels, however, a slight imbal-
ance was evident in triglyceride (TG) levels (Table 1).
2.2. Lipoprotein isolation from human plasma
Major lipoprotein classes were isolated from plasma samples by
sequential ultracentrifugation using table-top ultracentrifuge
(Beckmann Optima TL, USA) and KBr for density adjustment [12].
Serum sample (0.18e0.3mL) was first adjusted to the density (d) of
1.019 g/mL and the centrifuge tube filled with a d¼ 1.019 g/mL KBr
solution to the total volume of 3mL. The samples were centrifuged
at 5 C for 2 h at the speed 100,000 rpm (corresponding to relative
centrifugal force of 500,000g). After centrifugation, very low and
intermediate density lipoproteins (VLDL þ IDL) were recovered in
the top 1 mL fraction and the infranatant fraction was adjusted to
the density of 1.063 g/mL using solid KBr, filled again to final vol-
ume of 3 mL with d ¼ 1.063 g/mL KBr solution and centrifuged
(5 C, 3 h, 100,000 rpm). The top 1 mL fraction contained low
density lipoprotein (LDL) particles. To get the total HDL fraction the
infranatant fraction was adjusted with KBr to the density of 1.21 g/
mL, the vials filled with KBr density (1.21 g/mL) solution and then
centrifuged (5 C,18 h,100,000 rpm). Total HDLwas obtained in top
1 mL fraction. The isolated fractions were stored at 80 C before
analysis.
2.3. Lipidomic analysis of plasma and lipofractions
Lipids from total plasma and VLDL þ IDL, LDL and HDL particles
were extracted using a modified Folch lipid extraction [13,14] per-
formed on a Hamilton Microlab Star robot. Samples were spiked
with known amounts of non-endogenous synthetic internal stan-
dards. After lipid extraction, lipids were resolubilized in
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were added to the lipid extracts. The extracts were stored at20 C
prior to mass spectrometry (MS) analysis. For quantification of free
cholesterol (FC) from plasma, an aliquot of each lipid extract was
treated with acetyl chloride to derivatize FC tomodified cholesteryl
ester species.
In Shotgun Lipidomics, lipid extracts were analyzed using a
hybrid triple quadrupole/linear ion trap mass spectrometer (QTRAP
5500) equippedwith a robotic nanoflow ion source (NanoMate HD)
according to Ståhlman and colleagues [15]. Molecular lipids were
analyzed in both positive and negative modes using Multiple Pre-
cursor Ion Scanning (MPIS) based methods [16,17]. In plasma
samples, phospholipid species were analyzed with shotgun lip-
idomics, while in isolated lipoprotein fractions, phospholipids were
analyzed with an ultra-high pressure liquid chromatography
(UHPLC) system (Shimadzu Nexera 2 UHPLC or Eksigent XL-110
system) using multiple reaction monitoring (MRM) ebased
method in negative ion mode. Triacylglycerols (TAG) were analyzed
using Precursor Ion Scanning (PIS) and Neutral Loss scanning (NL)
based methods. The molecular lipid species were identified and
quantified in semi-absolute or absolute amounts [15]. Ceramides
were analyzed on a hybrid triple quadrupole/linear ion trap mass
spectrometer (5500 QTRAP) equipped with an ultra-high pressure
liquid chromatography (UHPLC) system (CTC HTC PAL autosampler
and Rheos Allegro pump) using multiple reaction monitoring
(MRM) ebased method in negative ion mode. Lipids were
normalized to their respective internal standard and the sample
amount. The concentrations of molecular lipids were presented as
mM. In lipoprotein fractions, lipids were also normalized with total
protein content of the lipoprotein particles (Micro BCA Protein
Assay Kit, Thermo Scientific).
2.4. Statistical analysis
Statistical analyses were performed using SAS version 9.4 and R
version 3.3.0. Due to smaller number of subjects than in the original
EQUATOR trial [11] and a slight imbalance of statin use in the
RG7652 and placebo groups, instead of the group-wise compari-
sons the statistical analyses were performed with paired t-test as
time-wise comparisons, using log-transformed concentrations.
Data were visualized using Tableau Desktop 8.2.1 and the per-
centage differences were calculated with pairwise comparisons:
presented differences are relative differences between group mean
values.
3. Results
3.1. PCSK9 inhibition impacts plasma sphingolipids and cholesterol
esters
Lipidomic analysis was performed from patients receiving anti-
PCSK9 therapy (RG7652) or placebo for 29 days (Table 1).
Congruent with previous report [11], 29 days after initiation of
treatment with RG7652, a marked decreasewas observed in plasma
levels of LDL-C, non-HDL-cholesterol (Non-HDL-C) and apolipo-
protein B-100 (apoB) while HDL-C was slightly increased (Fig. 1A).
No significant changes were detected in the placebo group. Overall,
administration of RG7652 resulted in decrease of most lipid classes
in plasma (Fig. 1B) and the results were consistent in subjects with
and without statin therapy (Supplementary Fig. 1). The most
affected lipid classes were sphingolipids including dihydrocer-
amides (Cer d18:0), globotriasoylceramides (Gb3), glucosyl/gal-
actosylceramides (Glc/GalCer), sphingomyelins (SM), ceramides
(Cer d18:1) and lactosylceramides (LacCer) (Fig. 1B, Supplementary
Fig. 2). A marked reduction was also observed in cholesteryl esters(CE) and free cholesterol (FC). Phospholipids as well as tri- and
diacylglycerols (TAG, DAG) were also reduced, but to a lesser extent
as compared with sphingolipids or CEs.
Several ceramide classes appeared to have a common trend
where, following PCSK9 inhibition, lipids with longer fatty acyl side
chains were reduced to a greater extent as compared to their
shorter fatty acyl side chain counterparts (Supplementary Fig. 2).
Consistent with this observation, ceramides containing very long
saturated fatty acid (22:0, 24:0 and 26:0) had a more substantial
reduction upon inhibition of PCSK9 when compared with the other
ceramide species (Fig. 1C). This same trend was not apparent for
other lipid classes such as sphingomyelins or cholesteryl esters
(Supplementary Fig. 2). We have recently reported that specific
ceramide ratios [Cer(d18:1/16:0)/Cer(d18:1:/24:0), Cer(d18:1/
18:0)/Cer(d18:1:/24:0) and Cer(d18:1/24:1)/Cer(d18:1:/24:0)] have
strong predictive value for fatal cardiovascular events [18], how-
ever, these ratios were not significantly altered due to the PCSK9
inhibition (Supplementary Fig. 2). In addition, eicosanoids did not
show major changes after RG7652 treatment.
3.2. Effect of PCSK9 inhibition on the lipidome of lipoproteins
The observed variable decrease of different sphingolipid and
cholesteryl ester species in plasma suggest that PCSK9 inhibition
does not solely decrease LDL particle number, but may also affect
the lipid composition of the lipoproteins. To test that, we isolated
VLDL þ IDL, LDL and HDL lipoprotein classes from plasma samples
followed by lipidomic profiling. First, we investigated how circu-
lating lipid load is shifted between lipoprotein particles due to
PCSK9 inhibition. As the PCSK9 inhibition appeared to have a
different effect on various ceramides in plasma, we analyzed their
relative distribution in the isolated lipoprotein classes at baseline
(Fig. 1D). Non-saturated 24:1-containing ceramides were shown to
be less abundant than 24:0- and 26:0-containing ceramides in LDL
particles, explaining why PCSK9 inhibition decreases less 24:1
containing ceramides than those with long saturated fatty acids in
plasma. When investigating the total lipid shift between lipopro-
tein particles, for all lipid classes the conclusionwas the same; after
RG7652 treatment LDL particles carried less lipids, while lipid
proportions in VLDL þ IDL were rather unchanged, and there was
relatively higher amount of lipids carried in the HDL particles
(Fig. 2A).
Next, we normalized the lipidomic data to the total protein
content of each lipoprotein fraction to account for changes in par-
ticle numbers. An overall decrease was observed on lipid class level
in LDL and VLDL þ IDL fractions after PCSK9 inhibition (Fig. 2B),
while no significant changes were observed in the placebo group
(Supplementary Fig. 3). The most pronounced reduction was
recorded for CEs and sphingolipids in both apoB-containing lipo-
protein fractions; in LDL fraction, phosphatidylcholines (PC) also
showed a strong decrease. In HDL particles, ceramides and dihy-
droceramides were predominantly decreased, while phospholipids
(PCs and phosphatidylethanolamines (PEs)) were increased after
PCSK9 inhibition.
As suggested by the total lipid class results presented above,
levels of practically all individual lipid species were reduced in the
LDL and VLDL þ IDL particles due to PSCK9 inhibition
(Supplementary Fig. 4). However, more variation was recorded
among the lipid species in HDL particles. For instance, some SM
species [SM (d18:1/16:0), SM (d18:1/16:1) and SM (d18:1/18:1)]
were increased in HDL while these SM species were strongly
reduced in VLDLþ IDL and LDL fractions. Furthermore, linoleic acid
(18:2) and arachidonic acid (20:4) containing phosphatidylcholines
(PCs) and phosphatidylethanolamines (PEs) were increased in the
HDL particles after PCSK9 inhibition. Finally, the aforementioned
Fig. 1. Changes of clinical variables and lipids in RG7652 and placebo groups.
Day 29 vs. day 1 comparisons of (A) lipid panel and laboratory measurements and (B) total lipid classes in RG7652 and placebo groups. (C) Change of ceramides according to their
fatty acid composition at day 29 vs. baseline. The mean change has been calculated based on the following lipid classes: Cer d18:0, Cer d18:1, Gb3, Glc/GalCer and LacCer. The
significance for the changes was calculated as compared to change in 16:0 ceramides. ***p < 0.001; **p < 0.01; *p< 0.05; p 0.05. (D) Distribution of 24:0, 24:1 and 26:0 containing
ceramides (Cer d18:0, Cer d18:1, Gb3, Glc/GalCer and LacCer) into different lipoprotein fractions at baseline.
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HDL particles.
To further investigate the relative changes in the lipid compo-
sition of different lipoprotein particles we calculated the relative
percentage of all lipid classes by dividing their concentration by the
total lipid concentration in the distinct lipoprotein fraction. In
general, CE concentration seemed to decrease in all lipoprotein
fractions (Table 2). This effect was particularly obvious in the
VLDL þ IDL fraction, where a significant relative decrease of 30%
was observed. Another common trend in all lipoprotein fractions
was significant relative increase in different phospholipid classes
(PC, PE, PI). Finally, the relative amount of triacylglycerols was
significantly increased in LDL and VLDL þ IDL fractions.4. Discussion
This study is the first one to characterize the lipidome of plasma
and isolated lipoprotein fractions following treatment with a PCSK9
inhibitor. PCSK9 inhibition resulted in significant decreases inplasma levels of several lipid classes, especially sphingolipids and
cholesteryl esters, and also affected the overall and relative distri-
bution of hundreds of different lipid species within and between
lipoprotein particles. The data reported here is consistent with
previously reported lipidomic data in plasma from PCSK9-deficient
mice and humans harboring a LOF mutation (R46L) in the PCSK9
gene [9]. Mice on a regular chow diet showed a strong reduction of
sphingolipids and cholesteryl esters, in line with the present hu-
man study. In humans with a PCSK9 LOF mutation, several lipid
classes including sphingolipids and cholesteryl esters showed
15e25% lower levels as compared to subjects with wild type PCSK9,
while the difference for LDL-C wasmoremodest (10%) [9]. Thus, the
remaining important question is whether reduction of biologically
active lipids, LDL-C, or both is more relevant and clinically sufficient
for the outcome of the patients.
Previous studies have shown that specific lipids, impacted also
by PCSK9 inhibition, can alter the progression of atherosclerosis
and their plasma levels can introduce further added predictive
value for the outcome of coronary artery disease [18e20]. Ceramide
Fig. 2. Lipid class distributions and changes in lipoprotein classes.
(A) Distribution of total lipid classes to different lipoprotein classes at baseline (D1) and day 29 (D29) for placebo and RG7652 groups. (B) Volcano plots showing the change of total
lipid classes at day 29 vs. baseline for lipidomic data normalized with total protein content of each lipoprotein class.
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cially fatal cardiovascular events in patients with stable coronary
artery disease and acute coronary syndrome [18]. Interestingly, the
degree of reduction of plasma ceramides in response to PCSK9 in-
hibitionwas dependent on ceramide fatty acyl chain length, or even
the number of double bonds. The reason for this phenomenon was
difference in the distribution of the ceramides in the lipoprotein
fractions. As an example, 24:1 fatty acid containing ceramides were
relatively less abundant in LDL than those incorporating 24:0 fatty
acid, leading to nonsignificant change of this cardiovascular death
associated plasma ceramide ratio after dramatic LDL-C lowering.
Interestingly, recent data from the FOURIER outcome trial showthat while prolonged PCSK9 inhibition significantly reduces non-
fatal CV events, there was no improvement in the risk reduction
of fatal cardiovascular events [8]. However, our previous results
from humans and mice with LOF in the PCSK9 gene showed greater
decrease for Cer(d18:1/16:0) and Cer(d18:1/18:0) than for
Cer(d18:1/24:0) [9], suggesting that modulation of PCSK9 activity
by antibodies or genetic background may affect the cardiovascular
death associated ceramide ratios differently. Although such link
between lipidomic changes and cardiovascular mortality requires
further validation, it suggests that lipid biomarkers, beyond LDL-C,
may hold important clues on the clinical progression of cardio-
vascular disease.
Table 2
Relative (%) lipid class composition of lipoprotein fractions at baseline (D1) and day 29 (D29).
Lipid class LDL VLDL þ IDL HDL
RG7652 Change (%)a Placebo RG7652 Change (%)a Placebo RG7652 Change (%)a Placebo
D1 D29 D1 D29 D1 D29 D1 D29 D1 D29 D1 D29
CE 82.1 77.7 5.4 81.6 81.7 45.9 32.1 30.0 45.8 46.5 70.2 65.5 6.6 70.5 70.6
PC 12.3 16.3 32.4 12.5 12.5 14.3 16.2 13.0 14.3 14.3 23.1 30.2 30.7 28.1 22.8
TAG 1.5 2.3 53.2 1.4 1.5 35.9 47.7 33.0 35.8 35.2 3.1 3.0 n.s. 2.7 2.7
SM 3.4 3.2 n.s. 3.8 3.7 2.3 2.1 10.3 2.4 2.4 2.9 3.1 n.s. 2.9 3.0
Cer d16:1 0.0083 0.0118 42.7 0.0082 0.0076 0.016 0.020 26.4 0.014 0.014 0.0066 0.0072 n.s. 0.0065 0.0056
Cer d18:0 0.0017 0.0019 n.s. 0.0018 0.0016 0.002 0.002 26.7 0.002 0.002 0.0011 0.0009 19.2 0.0010 0.0009
Cer d18:1 0.124 0.164 32.1 0.140 0.127 0.194 0.213 9.6 0.196 0.201 0.083 0.078 n.s. 0.092 0.078
Cer d18:2 0.015 0.023 53.3 0.017 0.015 0.033 0.043 30.0 0.035 0.033 0.013 0.015 n.s. 0.015 0.012
DAG e e e e e 0.410 0.551 n.s 0.425 0.416 0.034 0.037 n.s. 0.029 0.030
Gb3 0.028 0.031 n.s. 0.030 0.031 0.013 0.012 n.s 0.013 0.013 0.028 0.034 22.2 0.038 0.030
Glc/GalCer 0.19 0.20 n.s. 0.18 0.19 0.13 0.10 19.4 0.11 0.12 0.17 0.18 n.s. 0.18 0.15
LacCer 0.12 0.14 14.6 0.14 0.14 0.09 0.08 9.8 0.10 0.09 0.12 0.13 n.s. 0.15 0.12
LPC e e e e e 0.30 0.29 n.s 0.29 0.31 0.13 0.11 n.s. 0.15 0.14
PE 0.09 0.14 53.7 0.11 0.10 0.33 0.47 41.2 0.40 0.39 0.26 0.37 30.7 0.37 0.30
PI 0.07 0.10 37.3 0.07 0.08 0.09 0.11 19.4 0.10 0.10 0.19 0.24 27.6 0.23 0.19
Placebo group did not show significant changes in any of the comparisons.
a n.s., not significant (p 0.05).
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different lipid levels in LDL particles after PCSK9 inhibition, but also
that the relative lipid composition of the LDL, VLDL and HDL par-
ticles is altered. When looking at the relative lipid distribution
within the particles, a common phenomenon in all major lipopro-
tein classes was the systematic reduction of cholesteryl esters
which resulted in an increase in the other lipid classes. However,
when investigating the lipids normalized to total protein content of
the lipoproteins, it appeared that VLDL and LDL fractions had
significantly decreased levels of most of the lipid classes, suggesting
a decrease in their sizes, while in HDL fractions, phospholipidswere
increased. The substantial decrease of lipids versus protein ratio in
VLDL and LDL could imply that PCSK9 inhibition affects the lipid
content of the particles, particle size or the distribution of specific
lipoprotein classes. Although not observed in this substudy, anal-
ysis of the entire study population show a significant reduction in
LDL particle size following treatment with anti-PCSK9 [11]. In a
separate study an increase in HDL as well as VLDL particle size was
detected following PCSK9 inhibition [21]. It still remains to be
determined how these changes impact the functionality of the li-
poprotein particles. A potential limitation of our study is the lack of
proteomic data that could provide further information on the
changes in lipoprotein classes following marked reduction of LDL-
C.
Previous results have reported that PCSK9 inhibition, while
markedly reducing LDL-C, does not affect inflammatory markers,
such as CRP and pro-inflammatory cytokines [11,22]. Our current
finding demonstrating that the inflammation-related eicosanoids
[23] did not show major alterations may provide a mechanistic
explanation for this clinical observation. Nevertheless, in HDL
particles phospholipid species containing the inflammation related
arachidonic acid (20:4), and its precursor linoleic acid (18:2), were
increased more than the other phospholipid species. An increase of
these fatty acids in HDL particles may indicate that the arachidonic
acid in HDL particles is neutralized via hepatic HDL particle uptake
and degradation, thereby suggesting possible anti-inflammatory
effect on the cardiovascular system. However, additional studies
are needed to understand the significance of our observation.
In conclusion, our study revealed that antibody-mediated PCSK9
inhibition does not only affect LDL cholesterol metabolism, but also
alters the global lipidome both at the level of plasma and circu-
lating lipoprotein particles. Our results are also consistent withlipidomic alterations that have been described due to statin treat-
ment, as e.g. rosuvastatin has been shown to decrease sphingoli-
pids more than phospholipids, similar to the results of the present
study [24]. This suggests that although statins and anti-PCSK9 in-
hibitors work through different mechanism of actions, the major
driver for the observed treatment-related effect on the lipidome is
their overall LDL-lowering effect. Taken together the present and
previous results, it has become apparent that LDL-cholesterol
lowering therapies affect profoundly the plasma and lipoprotein
lipidome. It would be important to understand the relative
importance of all the other alterations in the lipidome, as compared
to the reduction of cholesterol content, in the prevention of car-
diovascular events. This can be achieved only by systematic analysis
on how the full lipidome of plasma and lipoprotein particles both
predict cardiovascular risk and how modifications of the lipidome
by PCSK9, statin or other lipid modifying therapies affect the
outcome of the patients.
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